US Patent Issued to Beijing Wisdomab Biotechnology, Genrix (Shanghai) Biopharmaceutical, Chongqing Genrix Biopharmaceutical on Dec. 30 for "Anti-CD3 and anti-CD123 bispecific antibody and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,509,520, issued on Dec. 30, was assigned to Beijing Wisdomab Biotechnology Co. Ltd (Beijing), Genrix (Shanghai) Biopharmaceutical Co. Ltd. (Shanghai) and Chongqing Genrix Biopharmaceutical Co. Ltd. (Chongqing, China).

"Anti-CD3 and anti-CD123 bispecific antibody and use thereof" was invented by Zhigang Liu (Beijing), Xiaobo Hao (Beijing), Xueping Zhang (Beijing), Yulan Liu (Beijing) and Jingjing Guo (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "A bispecific antibody having an antigen-binding portion for human CD3E and/or an antigen-binding portion for human CD123. Medical and biological uses of the bispecific antibody are also disclosed."

The...